Xiangyu Medical (688626) Fundamentals 2026 — P/E 81.9x, Revenue Analysis | SniperIQ
Xiangyu Medical (688626) is a CN-listed Healthcare company in Medical - Specialties with a market capitalization of ¥6.4B, trading at ¥41.68 on the SHH. This SniperIQ fundamentals page covers Xiangyu Medical's valuation (P/E 81.9x, P/B 3.1x), profitability (net margin 10.4%), revenue (¥768M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Xiangyu Medical's market cap?
Xiangyu Medical (688626) has a market capitalization of approximately ¥6.4B, trading at ¥41.68 on the SHH. Market cap moves with the live share price.
What is Xiangyu Medical's P/E ratio?
Xiangyu Medical's trailing twelve-month P/E ratio is 81.9x, with a price-to-book (P/B) of 3.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Xiangyu Medical?
Xiangyu Medical runs a net profit margin of 10.4%, a gross margin of 67.3%, and an operating margin of 9.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Xiangyu Medical generate?
Xiangyu Medical reported revenue of ¥768M for fiscal year 2025, with net income of ¥78M and earnings per share (EPS) of 0.51. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Xiangyu Medical pay a dividend?
Xiangyu Medical offers a trailing dividend yield of about 0.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Xiangyu Medical financially healthy?
Xiangyu Medical carries a debt-to-equity ratio of 0.32x and a current ratio of 1.68x, with a market beta of 0.59. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Xiangyu Medical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Xiangyu Medical (688626) the key facts are: market cap ¥6.4B, P/E 81.9x, revenue ¥768M, 52-week range 40.4-95. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Xiangyu Medical's full fundamentals live
Get Xiangyu Medical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.